Document is current
Any future updates will be listed below
-
Authors
Debureaux, Pierre-Edouard https://orcid.org/0000-0002-2358-4278
Kulasekararaj, Austin G. https://orcid.org/0000-0003-3180-3570
Cacace, Fabiana
Silva, Bruno G. P.
Calado, Rodrigo T.
Barone, Federica
Sicre de Fontbrune, Flore
Prata, Pedro Henrique https://orcid.org/0000-0003-0235-7890
Soret, Juliette
Sica, Michela
Notaro, Rosario
Scheinberg, Phillip
Mallikarjuna, Vasundhara
Gandhi, Shreyans
Large, Joanna
Risitano, Antonio M. https://orcid.org/0000-0002-4744-5109
Peffault de Latour, Regis
Frieri, Camilla
,
- License Information
-
More Information
Article History
Received: 8 January 2021
Revised: 12 May 2021
Accepted: 1 June 2021
First Online: 5 July 2021
Competing interests
: AGK has received Honoraria from Alexion, Celgene, Novartis, Amgen, Ra Pharma. FSF has received Honoraria and research funding from Alexion and Novartis. RN has received lecture fees from Alexion and has served as member of an advisory board for Biocryst. AMR has received research funding from Ra Pharma, Achillion, Novartis, Apellis, Alexion, Alnylam and received Honoraria from Pfizer, Appelis, and Alexion. RPL has received research funding from Pfizer, Alexion, Novartis and Amgen. Other authors declare no competing financial interests.
